SCHEDULE: State Street Discloses 4.2% Stake in Celldex Therapeutics

State Street Corporation has reported beneficial ownership of 2,804,168 shares, representing 4.2% of the outstanding common stock of Celldex Therapeutics, as of March 31, 2026.

Summary

• State Street Corporation, through its subsidiaries, has filed a Schedule 13G indicating it beneficially owns 2,804,168 shares of Celldex Therapeutics' common stock.
• This ownership stake represents 4.2% of the class of securities.
• The filing is made under Rule 13d-1(b), classifying State Street Corporation as a significant institutional holder.
• The reporting date for this ownership is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral score, as the filing is a standard disclosure of institutional ownership and does not provide new operational or financial performance information about Celldex Therapeutics itself.

Positives

• State Street Corporation, a major financial institution, holds a significant stake in Celldex Therapeutics, which could be interpreted as a vote of confidence in the company's long-term prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Risks

• As a Schedule 13G filer, State Street is generally a passive investor, meaning their investment does not inherently signal an activist stance or a desire to influence company strategy, which could be a neutral or negative factor for investors seeking active institutional support.

Future Outlook

The filing does not contain forward-looking statements or guidance from Celldex Therapeutics. It solely reports the ownership stake of State Street Corporation.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G from a major entity like State Street Corporation are common for tracking significant ownership changes and can provide insights into institutional sentiment towards biotechnology companies, which are often subject to volatility based on clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may influence market perception but does not directly alter company operations or immediate shareholder value without further action from State Street.

Key Dates

Keywords

Celldex Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing